文献速递消化道肿瘤放疗姑息放疗与转移瘤

根治性放疗用于食管癌初始治疗后异时性寡转移

Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer.
PubMed 文献 · Radiother Oncol · 2020-09-25

该回顾性研究纳入82例初始根治性治疗后的异时性寡转移食管癌患者,比较放疗与非放疗的疗效。放疗组中位总生存14个月,非放疗组7个月(P=0.016);多因素分析显示治疗方式为独立预后因素。根治性放疗(BED10≥60 Gy)可能延长生存,且未观察到3级以上毒性。

要点

  • 放疗组中位总生存14个月,非放疗组7个月(P=0.016)。
  • BED10≥60 Gy组中位总生存16个月,低于60 Gy组10个月(P=0.033)。
  • 治疗方式(放疗 vs 非放疗)为独立预后因素(HR=1.8,95%CI 1.1-3.0;P=0.022)。

核心结论

  • 对初始根治性治疗后的异时性寡转移食管癌患者,放疗是可行且积极的治疗选择。
  • 根治性放疗剂量BED10≥60 Gy有助于延长生存,应考虑用于此类患者。

研究设计与样本

  • 回顾性分析2009-2018年绵阳市中心医院收治的82例异时性寡转移食管癌患者,每例≤5个寡转移灶且原发灶控制。
  • 患者分为放疗组(接受调强放疗)和非放疗组,研究终点为总生存和治疗毒性。

主要发现

  • 放疗组与非放疗组中位总生存分别为14个月(95%CI 11.0-17.0)和7个月(95%CI 4.5-9.5),P=0.016。
  • 肺转移与骨转移患者中位总生存分别为18个月(95%CI 13.6-22.4)和10个月(95%CI 5.1-14.9),P=0.010。
  • 初始诊断至转移间隔≥12个月与<12个月患者中位总生存分别为15个月(95%CI 12.4-17.6)和10个月(95%CI 7.6-12.4),P=0.026。
  • BED10≥60 Gy与<60 Gy患者中位总生存分别为16个月(95%CI 12.2-19.8)和10个月(95%CI 5.0-15.0),P=0.033。
  • Cox多因素分析显示治疗方式(放疗 vs 非放疗)为独立预后因素(HR=1.8,95%CI 1.1-3.0;P=0.022)。

关键数值与推荐

  • 所有患者均未观察到大于3级的毒性副作用。

临床怎么用

  • 对初始治疗后原发灶控制的异时性寡转移食管癌患者,可考虑给予根治性放疗。
  • 放疗剂量建议达到BED10≥60 Gy以获取生存获益。

局限性

  • 本研究为单中心回顾性分析,样本量82例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study aimed to evaluate the efficacy of radical radiotherapy and assess prognostic factors in metachronous oligometastatic esophageal cancer (MOEC) patients after initial treatment with curative-intent surgery and/or chemoradiotherapy. MATERIALS AND METHODS: MOEC Patients during 2009-2018 in Mianyang Central Hospital were retrospectively analyzed. Each patient had ≤5 oligometastatic lesions, and the primary lesions were controlled in this study. Patients were devided into radiotherapy (RT) and non-radiotherapy (NRT) groups. The study endpoints were overall survival (OS) and treatment toxicities. RESULTS: This study included 82 patients who underwent intensity-modulated radiotherapy for MOEC. Median OS were 14 (95% confidence interval [CI], 11.0-17.0) and 7 (95% CI, 4.5-9.5) months for the RT and NRT groups, respectively (P = 0.016). Median OS were 18 (95% CI, 13.6-22.4) and 10 (95% CI, 5.1-14.9) months for lung and bone metastases, respectively (P = 0.010). Median OS were 15 (95% CI, 12.4-17.6) and 10 (95% CI, 7.6-12.4) months for interval time from initial diagnosis to metastasis ≥12 and <12 months, respectively (P = 0.026). Median OS were 16 (95% CI, 12.2-19.8) and 10 (95% CI, 5.0-15.0) months for biological effective dose (BED10) ≥ 60 Gy and BED10 < 60 Gy, respectively (P = 0.033). Cox multivariate regression analysis showed that treatment modality (RT vs. NRT) was an independent prognostic factor for MOEC patients (hazard ratio: 1.8, 95% CI: 1.1-3.0; P = 0.022). No toxic side effects greater than grade 3 were observed in all patients. CONCLUSIONS: Radiotherapy is a feasible and positive treatment for MOEC patients after initial treatment, a radical radiation dose with BED10 ≥ 60 Gy has benefits in extending survival. Radical radiotherapy should thus be considered for MOEC patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Li J, Wen Y, Xiang Z, et al. Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer. Radiother Oncol. 2020. PMID: 32980382. doi:10.1016/j.radonc.2020.09.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。